Clinical Trial Update: Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 safety study of a recombinant Listeria monocytogenes–based vaccine for HPV-16–positive oropharyngeal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Cancer

Drugs mentioned

• Recombinant Listeria monocytogenes-based vaccine

Snippet

Sponsor: University of Liverpool | Conditions: HPV-16 +ve Oropharyngeal Carcinoma | Phase 1 | Status: TERMINATED